These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 699334)

  • 1. The quantitative determination of 5-S-cysteinyldopa and dopa in normal serum and in serum from patients with malignant melanoma by means of high-pressure liquid chromatography.
    Hansson C; Edholm LE; Agrup G; Rorsman H; Rosengren AM; Rosengren E
    Clin Chim Acta; 1978 Sep; 88(3):419-27. PubMed ID: 699334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-S-Cysteinyldopa and dopa in serum during treatment with 8-methoxypsoralen and UVA light.
    Hansson C; Rorsman H; Rosengren E; Tegner E
    Acta Derm Venereol; 1981; 61(3):251-5. PubMed ID: 6167110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of DOPA, dopamine, and 5-S-cysteinyl-DOPA in plasma, urine, and tissue samples by high-performance liquid chromatography with electrochemical detection.
    Ito S; Kato T; Maruta K; Fujita K; Kurahashi T
    J Chromatogr; 1984 Nov; 311(1):154-9. PubMed ID: 6440898
    [No Abstract]   [Full Text] [Related]  

  • 4. Plasma 5-S-cysteinyldopa differentiates patients with primary and metastatic melanoma from patients with dysplastic nevus syndrome and normal subjects.
    Peterson LL; Woodward WR; Fletcher WS; Palmquist M; Tucker MA; Ilias A
    J Am Acad Dermatol; 1988 Sep; 19(3):509-15. PubMed ID: 3139723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-S-cysteinyldopa, dopa, and dopamine in the kidney and some other tissues.
    Agrup G; Hansson C; Rorsman H; Rosengren E
    Acta Derm Venereol; 1980; 60(1):63-4. PubMed ID: 6153836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of urinary 5-S-cysteinyldopa by high-performance liquid chromatography.
    Kågedal B; Pettersson A
    J Chromatogr; 1983 Feb; 272(2):287-97. PubMed ID: 6403561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Automated high-performance liquid chromatographic determination of 5-S-cysteinyl-3,4-dihydroxyphenylalanine in urine.
    Kågedal B; Källberg M; Arstrand K; Hansson C
    J Chromatogr; 1989 Jul; 473(2):359-70. PubMed ID: 2504759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma 5-S-cysteinyldopa concentrations in oculocutaneous albinism.
    Nimmo JE; Hunter JA; Percy-Robb IW; Jay B; Phillips CI; Taylor WO
    Acta Derm Venereol; 1985; 65(2):169-71. PubMed ID: 2408424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liquid-chromatographic determination of 5-S-L-cysteinyl-L-dopa with electrochemical detection in urine prepurified with a phenylboronate affinity gel.
    Kågedal B; Pettersson A
    Clin Chem; 1983 Dec; 29(12):2031-4. PubMed ID: 6416708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved method for analysis of cysteinyldopa in human serum.
    Arstrand K; Kullman A; Andersson R; Rasmuson T; Kågedal B
    Scand J Clin Lab Invest; 2004; 64(6):559-64. PubMed ID: 15370461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cysteinyldopa isomers and dopa in lesions and urine of Japanese patients with malignant melanoma.
    Morishima T; Tatsumi F; Fukada E; Saito M; Fujita M; Nagashima N; Hanawa S
    Arch Dermatol Res; 1983; 275(2):76-9. PubMed ID: 6409012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative determination of 5-S-cysteinyldopa, dopa and dopamine in the urine by means of high-performance liquid chromatography. A comparison with data obtained by means of fluorometry.
    Morishima T; Saito M; Hanawa S
    J Dermatol; 1981 Aug; 8(4):301-4. PubMed ID: 6795251
    [No Abstract]   [Full Text] [Related]  

  • 13. 5-S-cysteinyldopa in the urine of melanoma patients.
    Agrup G; Agrup P; Andersson T; Falck B; Hansson JA; Jacobsson S; Rorsman H; Rosengren E; Rosengren AM
    Acta Derm Venereol; 1977; 57(2):113-6. PubMed ID: 71802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy.
    Wimmer I; Meyer JC; Seifert B; Dummer R; Flace A; Burg G
    Cancer Res; 1997 Nov; 57(22):5073-6. PubMed ID: 9371505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary 5-S-cysteinyldopa in Parkinsonism after DOPA and carbidopa.
    Stewart RM; Miller S; Gunder M
    Acta Derm Venereol; 1983; 63(2):97-101. PubMed ID: 6189350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of serum 5-S-cysteinyl-dopa as a biomarker for predicting prognosis and detecting relapse in patients with advanced stage malignant melanoma.
    Umemura H; Yamasaki O; Kaji T; Otsuka M; Asagoe K; Takata M; Iwatsuki K
    J Dermatol; 2017 Apr; 44(4):449-454. PubMed ID: 27786364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopa and 5-S-cysteinyldopa in the serum of albino, black, and red guinea pigs.
    Hansson C; Agrup G; Rorsman H; Rosengren E
    Acta Derm Venereol; 1980; 60(2):155-56. PubMed ID: 6155023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of phaeomelanin and its precursor 5-S-cysteinyldopa in the serum of melanoma patients.
    Wakamatsu K; Yokochi M; Naito A; Kageshita T; Ito S
    Melanoma Res; 2003 Aug; 13(4):357-63. PubMed ID: 12883361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of 5-S-cysteinyldopa in plasma and urine using a fully automated solid-phase extraction--high-performance liquid chromatographic method for an improvement of specificity and sensitivity of this prognostic marker of malignant melanoma.
    Hartleb J; Damm Y; Arndt R; Christophers E; Stockfleth E
    J Chromatogr B Biomed Sci Appl; 1999 Apr; 727(1-2):31-42. PubMed ID: 10360420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma 5-S-cysteinyldopa correlates with tumor size in melanoma-bearing mice.
    Hu F; Woodward WR; Peterson LL
    J Invest Dermatol; 1988 Feb; 90(2):149-51. PubMed ID: 3123557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.